Management of Asymptomatic Atrial Fibrillation with Rapid Ventricular Response

Rationale for Beta-Blocker Selection

The American Heart Association recommends beta-blockers as the first-line treatment for rate control in patients with atrial fibrillation and cardiomyopathy, with a goal of achieving a resting heart rate <80 bpm for symptomatic management or <110 bpm for lenient control, as they are a Class I recommendation for rate control in persistent or permanent AF 1, 2
In patients with cardiomyopathy, beta-blockers are the preferred choice for both short- and long-term rate control, as they address both the tachycardia and provide cardioprotective benefits in the setting of underlying structural heart disease, according to the American College of Cardiology 3
Bisoprolol is a suitable option as it is a cardioselective beta-1 blocker that can be safely initiated orally in hemodynamically stable patients, with typical dosing of 2.5-10 mg daily, as recommended by the European Society of Cardiology 4

The American College of Cardiology advises against the use of non-dihydropyridine calcium channel blockers, such as verapamil, in patients with cardiomyopathy and potential heart failure, as they can exacerbate hemodynamic compromise and worsen ventricular function 1, 2
Digoxin should not be used as the sole agent to control ventricular rate in patients with paroxysmal AF, as it is a Class III recommendation, and is only considered as a second-line add-on therapy when beta-blockers are contraindicated or insufficient, according to the Heart Rhythm Society 1, 3

The European Society of Cardiology recommends that stroke risk stratification using CHA₂DS₂-VASc score must be performed, with anticoagulation recommended for scores ≥2 in men or ≥3 in women, and given the patient has cardiomyopathy, anticoagulation is likely indicated regardless of symptom status 3, 5
Sustained uncontrolled tachycardia can lead to deterioration of ventricular function, which improves with adequate rate control within 6 months, as stated by the American Heart Association 1

The American College of Cardiology recommends initiating bisoprolol starting at 2.5-5 mg daily, titrating up to 10 mg as needed for rate control, with a target heart rate goal of <80 bpm initially, and lenient control (<110 bpm) may be acceptable if the patient remains asymptomatic 2, 3
The Heart Rhythm Society suggests considering adding digoxin if beta-blocker monotherapy provides inadequate rate control, particularly if there is evidence of heart failure 3, 4

The American College of Cardiology advises against the use of dronedarone for rate control in permanent AF, as it increases risk of stroke, MI, and cardiovascular death 2